o2h Ventures

o2h Ventures focuses on seeding early-stage biotech therapeutics and related AI opportunities, particularly in the UK. The firm operates two funds: the Human Health EIS Knowledge Intensive Fund and the Human Health SEIS Fund. The EIS fund invests in companies qualifying under EIS and covering novel drug discovery along with enabling services, tools, and AI technologies. The SEIS fund targets seed-stage companies with a similar focus. o2h Ventures differentiates itself through grassroots working relationships, providing early access to deals. They aim to build a diversified portfolio of 5-10 companies and seek exits typically within 3-7 years, strategically managing exits to optimize S/EIS tax reliefs. They evaluate companies based on scientific tractability, IP position, path to the clinic, and the team's ability to navigate challenges, also attempting to gauge interest from potential acquirers early in the evaluation process. The firm actively nurtures and invests in emerging life science and tech companies, leveraging a strong pipeline of early-stage opportunities developed over 20 years of involvement in grassroots science in the UK. They operate from The Mill SciTech Park, a 2.7-acre site developed as an incubation hub for small life science companies. o2h Ventures' business model combines access to opportunities similar to China's Wuxi Ventures with an incubation approach akin to USA's Atlas Ventures, aiming to improve the prospects of successful exits. o2h Ventures emphasizes early involvement with founders, providing not only capital but also co-working lab and office space, hands-on scientific input, and ongoing board-level mentorship and strategic support. This integrated approach aims to help companies focus on innovation and rapid development. They also provide support through their research services company, o2h Discovery. The firm's investment strategy is knowledge-intensive, focusing on areas where they have deep expertise and can provide significant value beyond just capital.

Biotech therapeutics, AI, enabling services, novel drug discovery, tools, related AI opportunities

Core thematic spaces, technologies, and target market segments of interest.